Immuvera Therapeutics on the Radforsk Podcast
Our CEO, Jørund Sollid, recently joined the Radforsk podcast to talk about Immuvera’s journey so far, the road ahead, and how Norway can build a stronger health industry. He also shared reflections from his own career and what drives our work at Immuvera.
Written by
Immuvera
👉 Tune in on Soundcloud or Spotify
At Immuvera, we are pioneering a new immunotherapy for cancer in dogs – with the goal of preventing and treating lung metastases. In 2026, we will launch a randomized clinical trial with 40 dogs across 20 veterinary clinics in Europe. Looking ahead, our ambition is clear: a deal-exit in late 2027, followed by regulatory approval and market introduction in 2029 – bringing a much-needed treatment to dogs and their owners worldwide.
As part of this next chapter, we are raising new funding through Folkeinvest.
